News

The combination of Galenica's Vifor Pharma business unit with Relypsa will create a significant player in cardio-renal care in the US and further strengthen Vifor Pharma's growing international

Arcus raised an additional $70m in equity capital from Taiho Ventures, GV, Invus, DROIA Oncology Ventures and Stanford University, together with its Series A investors, including The Column

An independent adjudication and analysis of major adverse cardiovascular events confirmed an increased risk of stroke. The company said while odanacatib reduces the risk of osteoporotic fractures, the

The US Biomedical Advanced Research and Development Authority (BARDA) has selected the company’s vaccine business unit to develop an inactivated, adjuvanted, whole Zika virus vaccine. Takeda will receive

The study met its co-primary endpoints and showed a statistically significant and clinically meaningful improvement in overall survival (OS) compared with docetaxel chemotherapy in people with locally advanced

INTEGA, financially backed by Knight Therapeutics (TSX:GUD) and Bloom Burton Healthcare Lending Trust, owns the Canadian distribution rights for a number of well-known and established skin care brands,

This indication is approved under accelerated approval, and continued approval may be contingent upon verification of clinical benefit in subsequent trials. The approval is based on results from

The Ministry of Health (MOH) said that 24 new cases have been identified and a new potential cluster has been discovered at Bedok North Avenue 3. A pregnant

The proprietary platform centers on the use of a naturally occurring sugar polymer, heparosan, which is produced by the body and is naturally biodegradable. The platform includes a